Darinaparsin is under clinical development by Solasia Pharma and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase II drugs for Peripheral T-Cell Lymphomas (PTCL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Darinaparsin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Darinaparsin overview

Darinaparsin (Darvias) is an organoarsenic derivative. It is formulated as powder for solution for intravenous drip route of administration. Darvias is indicated for relapsed or refractory peripheral t-cell lymphoma in adults.

Darinaparsin (Zinapar, ZIO-101) is under development for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell Lymphoma (AITL), and anaplastic large cell lymphoma (ALCL). The drug candidate is administered through injection, intravenously and orally. Darinaparsin is organic arsenic derivative. It was also under development for treatment of solid tumors, relapsed/refractory acute leukemia, chronic myeloproliferative disease, chronic lymphoproliferative disease, lymphoma, myelodysplasia, Non-Hodgkin lymphoma and Hodgkin lymphoma, refractory/relapsed multiple myeloma, pancreatic cancer, prostate cancer, adult T-cell leukemia, acute myeloid leukemia (AML), and hepatocellular carcinoma.

Solasia Pharma overview

Solasia Pharma, formerly JapanBridge, is a pharmaceutical company that provides patient access to oncology therapies. The company develops and commercializes oncology therapies and cancer supportive care products. It develops SP-01, a transdermal delivery system, which delivers the anti-emetic and granisetron in the patient’s bloodstream without the need for injections and swallowing pills; and SP-02, a mitochondrial-targeted agent used for the treatment of various hematologic and solid cancers. Solasia Pharma offers SP-03, an oral liquid for the treatment of pain associated with oral mucositis and SP-04. The company markets its products to Japan, China and Asian countries. Solasia Pharma is headquartered in Tokyo, Japan

For a complete picture of Darinaparsin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.